Brian K. Link, M.D.
Professor
Interim Director of Clinical Services, Division of Hematology, Oncology and Blood & Marrow Transplantation
Dr. Link's clinical and research interests focus on the immunotherapy of lymphoid malignancies. He is the principal investigator on a number of protocols utilizing monoclonal antibodies and other immunomodulators for use in the therapy of human lymphoid malignancies.
Honors, Awards, and Organizations
- American College of Physicians
- American Association for Cancer Research
- American Society of Hematology
- American Society of Clinical Oncology
Recent Publications
- McLaughlin, Peter, Grillo-Lopez, Antonio J., Link, Brian K., Levy, Ron, Czuczman, Nyron S., Williams, Michael E., Heyman, Meyer R., Bence-Bruckler, Isabelle, Jain, Vinay, Ho, Anthony D., Lister, John, White, Christine A., Cabanillas, Fernando, Wey, Ken, Shen, David, Dallaire, Brian K. Chimeric Anti-CD20 Monoclonal Antibody therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a 4-Dose Treatment Program. Journal Clinical Oncology, 168) 2825-2833, 1998.
- Davis, TA, White CA, Grillo-Lopez AJ, Velazquez WS, Link BK, Maloney DG, Dillman RO, Williams ME, Mohrbacher R, Weaver R, Dowden S and Levy R. Single Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab. J. Clin. Oncol., 17(6), 1851-1857, 1999.
- Byrd, JC, White, CA, Link, B, Lucas, M, Velasquez, WS, Rosenberg, J, Grillo-Lopez, AJ: Rituximab therapy in Waldenstrom's macroglobulinema: Preliminary evidence of clinical activity. Ann Oncol 10(12):1525-7,1999.
- Click here for additional publications.
|
Medical School:
The University of Iowa
Residency:
Rush Presbyterian St. Luke's Hospital, Chicago
Fellowship:
The University of Iowa |
